Articles By Rob Wright, Chief Editor 2011-2021
-
Details Of Dr. Oz Ambush Dished Up During 2013 DIA7/15/2013
At this year’s DIA meeting in Boston, we tried something a little different, thanks to an idea presented to us by LabCorp, which approached us expressing interest in creating an educational/networking opportunity. By Rob Wright
-
Is Closing Your Manufacturing Plant The Best Option?7/9/2013
This year there have been a number of companies announcing pharmaceutical manufacturing plant closures. For example, Catalent Pharma Solutions announced the closing of its Allendale, NJ, facility. Solgar Inc., a subsidiary of NBTY, announced the closing of its plant in Lyndhurst, NJ. These pharma manufacturing plant closings equate to 196 jobs lost for New Jersey.
-
A Life Science Revolution Is Happening Now7/2/2013
To me, it seemed fitting that this year’s annual DIA meeting (June 23 – 27) was held in Boston, a city synonymous with the American Revolution. By Rob Wright
-
J&J's Approach To Drug Discovery And Breakthrough Therapy7/1/2013
One year ago, the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law. Its most current version includes a provision that allows sponsor companies to request their drug be designated as a “breakthrough therapy.” In February, Johnson & Johnson (J&J) became only the second company (behind Vertex Pharmaceuticals) to have a drug receive this designation.
-
The Secret To True Strategic Partnerships6/24/2013
In the May 2013 issue of Life Science Leader magazine, Wayne Koberstein wrote an article asking the question, When Does a Supplier Become A Partner? I shared Koberstein’s skepticism when he said, “Just doing business with a developer doesn’t make you a partner. By Rob Wright
-
When Was The Last Time You Worked On The Front Lines6/10/2013
When I met Jeff Williams, CEO of Clinipace, the intent was to learn about the business. But in so doing, my natural curiosity got the best of me — inquiring how he got started in the business. By Rob Wright
-
Can Pharma And Biotech Companies Trust Emerging Markets To Protect IP?5/30/2013
How long can or should biotech and pharmaceutical companies continue to conduct business in regions where there is government-enabled IP theft?
-
MedImmune's Blueprint For Building A Biologics R&D Engine5/30/2013
Bahija Jallal, VP of translational science for MedImmune, has some insights on how to successfully focus your biologics R&D operation to encourage, not kill the entrepreneurial spirit on which it was built.
-
The Most Creative Collaborations In Healthcare5/28/2013
This was the question I posed to the panel members of the DSM-sponsored Healthcare Businesswomen’s Association (HBA) Metro Chapter program entitled Creative Collaborations in Healthcare. By Rob Wright